Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Cash from Operations (2020 - 2025)

Historic Cash from Operations for HCW Biologics (HCWB) over the last 6 years, with Q3 2025 value amounting to -$3.2 million.

  • HCW Biologics' Cash from Operations fell 1071.15% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.9 million, marking a year-over-year increase of 1580.63%. This contributed to the annual value of -$14.2 million for FY2024, which is 3680.66% up from last year.
  • Latest data reveals that HCW Biologics reported Cash from Operations of -$3.2 million as of Q3 2025, which was down 1071.15% from -$3.3 million recorded in Q2 2025.
  • In the past 5 years, HCW Biologics' Cash from Operations registered a high of -$990440.0 during Q2 2021, and its lowest value of -$9.4 million during Q2 2023.
  • Its 5-year average for Cash from Operations is -$3.6 million, with a median of -$3.4 million in 2021.
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 5478.03% in 2022, then plummeted by 24916.05% in 2023.
  • HCW Biologics' Cash from Operations (Quarter) stood at -$3.4 million in 2021, then fell by 12.22% to -$3.8 million in 2022, then decreased by 2.78% to -$3.9 million in 2023, then grew by 27.21% to -$2.8 million in 2024, then fell by 14.29% to -$3.2 million in 2025.
  • Its Cash from Operations was -$3.2 million in Q3 2025, compared to -$3.3 million in Q2 2025 and -$3.5 million in Q1 2025.